Which has stronger earnings and valuation, CRDL or IVA?

Cardiol Therapeutics has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Inventiva $5.07M 129.46 -$400.67M N/A N/A

Is CRDL or IVA more profitable?

Inventiva's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Inventiva N/A N/A N/A

Which has higher earnings & valuation, CRDL or GLAS?

Cardiol Therapeutics has higher earnings, but lower revenue than Glass House Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Glass House Brands $181.98M 2.18 -$29.66M N/A N/A

Cardiol Therapeutics (CRDL) Competitors

$1.23 -0.07 (-5.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.03 (+2.20%)

As of 07:55 PM Eastern

Compare

CRDL vs. COLL, IVA, ZVRA, GLAS, and CRMD

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Collegium Pharmaceutical (COLL), Inventiva (IVA), Zevra Therapeutics (ZVRA), Glass House Brands (GLAS), and CorMedix (CRMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Cardiol Therapeutics (NASDAQ:CRDL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cardiol Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 713.01%. Collegium Pharmaceutical has a consensus target price of $48.71, suggesting a potential upside of 120.53%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Collegium Pharmaceutical has a net margin of 5.93% compared to Cardiol Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Collegium Pharmaceutical has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Collegium Pharmaceutical	$780.57M	0.92	$62.87M	$1.24	17.81

In the previous week, Collegium Pharmaceutical had 7 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for Collegium Pharmaceutical and 1 mentions for Cardiol Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.03 beat Cardiol Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Collegium Pharmaceutical	Neutral

Cardiol Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Inventiva?

Cardiol Therapeutics (NASDAQ:CRDL) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Cardiol Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 713.01%. Inventiva has a consensus price target of $15.86, indicating a potential upside of 401.81%. Given Cardiol Therapeutics' higher probable upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cardiol Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Inventiva	$5.07M	129.46	-$400.67M	N/A	N/A

Inventiva's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Inventiva	N/A	N/A	N/A

Cardiol Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Inventiva had 8 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 9 mentions for Inventiva and 1 mentions for Cardiol Therapeutics. Inventiva's average media sentiment score of 0.50 beat Cardiol Therapeutics' score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Inventiva	Positive

Summary

Inventiva beats Cardiol Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Zevra Therapeutics had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for Zevra Therapeutics and 1 mentions for Cardiol Therapeutics. Zevra Therapeutics' average media sentiment score of 0.96 beat Cardiol Therapeutics' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Zevra Therapeutics	Positive
Cardiol Therapeutics	Neutral

Zevra Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.35	$83.23M	$0.92	12.38
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Zevra Therapeutics currently has a consensus price target of $27.14, suggesting a potential upside of 138.30%. Cardiol Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 713.01%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zevra Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has a net margin of 42.82% compared to Cardiol Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Summary

Zevra Therapeutics beats Cardiol Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Glass House Brands?

Cardiol Therapeutics (NASDAQ:CRDL) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Cardiol Therapeutics has higher earnings, but lower revenue than Glass House Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Glass House Brands	$181.98M	2.18	-$29.66M	N/A	N/A

Cardiol Therapeutics has a net margin of 0.00% compared to Glass House Brands' net margin of -29.48%. Glass House Brands' return on equity of -58.76% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Glass House Brands	-29.48%	-58.76%	-15.14%

Cardiol Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 713.01%. Glass House Brands has a consensus target price of $16.00, suggesting a potential upside of 274.80%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Glass House Brands'average media sentiment score.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Glass House Brands	Neutral

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cardiol Therapeutics beats Glass House Brands on 7 of the 10 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

CorMedix has a net margin of 40.49% compared to Cardiol Therapeutics' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

34.2% of CorMedix shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CorMedix presently has a consensus target price of $15.00, suggesting a potential upside of 103.25%. Cardiol Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 713.01%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, CorMedix had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for CorMedix and 1 mentions for Cardiol Therapeutics. CorMedix's average media sentiment score of 0.83 beat Cardiol Therapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Positive
Cardiol Therapeutics	Neutral

CorMedix has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$457.20M	1.26	$163.05M	$2.14	3.45
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

CorMedix has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Summary

CorMedix beats Cardiol Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$154.61M	$12.34B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	20.71%
P/E Ratio	-4.92	797.58	274.13	26.16
Price / Sales	N/A	754.39	589.97	95.24
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	11.18	10.71	11.21	6.34
Net Income	-$24.20M	$2.84B	$3.50B	$381.90M
7 Day Performance	-12.77%	-0.99%	-0.84%	-1.39%
1 Month Performance	-46.29%	-5.86%	-5.42%	-4.31%
1 Year Performance	12.84%	-5.32%	4.38%	-0.35%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	2.4176 of 5 stars	$1.23 -5.4%	$10.00 +713.0%	+20.4%	$154.61M	N/A	N/A	18
COLL Collegium Pharmaceutical	3.9423 of 5 stars	$22.28 -1.6%	$48.71 +118.7%	-33.3%	$724.27M	$780.57M	17.94	423	Analyst Downgrade
IVA Inventiva	3.3247 of 5 stars	$3.47 -1.8%	$15.75 +354.2%	-38.1%	$721.79M	$5.07M	N/A	73	Analyst Downgrade Short Interest Increase
ZVRA Zevra Therapeutics	4.4038 of 5 stars	$11.28 -0.2%	$27.14 +140.6%	+3.4%	$670.16M	$106.47M	12.27	61	News Coverage
GLAS Glass House Brands	2.1387 of 5 stars	$6.60 -3.6%	$16.00 +142.3%	N/A	$618.33M	N/A	N/A	357	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. COLL, IVA, ZVRA, GLAS, and CRMD

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Cardiol Therapeutics compare to Inventiva?

Summary

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Summary

How does Cardiol Therapeutics compare to Glass House Brands?

Summary

How does Cardiol Therapeutics compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. COLL, IVA, ZVRA, GLAS, and CRMD

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Do insiders and institutionals have more ownership in CRDL or COLL?

Do analysts recommend CRDL or COLL?

Is CRDL or COLL more profitable?

Which has higher earnings and valuation, CRDL or COLL?

Does the media prefer CRDL or COLL?

Which has more risk and volatility, CRDL or COLL?

Summary

How does Cardiol Therapeutics compare to Inventiva?

Do analysts prefer CRDL or IVA?

Which has stronger earnings and valuation, CRDL or IVA?

Is CRDL or IVA more profitable?

Which has more risk & volatility, CRDL or IVA?

Do insiders & institutionals hold more shares of CRDL or IVA?

Does the media favor CRDL or IVA?

Summary

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Does the media refer more to ZVRA or CRDL?

Which has higher earnings & valuation, ZVRA or CRDL?

Do analysts rate ZVRA or CRDL?

Which has more risk & volatility, ZVRA or CRDL?

Do insiders and institutionals have more ownership in ZVRA or CRDL?

Is ZVRA or CRDL more profitable?

Summary

How does Cardiol Therapeutics compare to Glass House Brands?

Which has higher earnings & valuation, CRDL or GLAS?

Is CRDL or GLAS more profitable?

Do analysts recommend CRDL or GLAS?

Does the media refer more to CRDL or GLAS?

Do insiders & institutionals believe in CRDL or GLAS?

Summary

How does Cardiol Therapeutics compare to CorMedix?

Is CRMD or CRDL more profitable?

Do institutionals and insiders believe in CRMD or CRDL?

Do analysts prefer CRMD or CRDL?

Does the media refer more to CRMD or CRDL?

Which has higher valuation and earnings, CRMD or CRDL?

Which has more volatility & risk, CRMD or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools